Salvage endoscopic resection as a treatment for locoregional failure or recurrence following chemoradiotherapy or radiotherapy for esophageal cancer
Authors:
Open Access
- 20 April 2016
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (6) , 3631-3636
Abstract
Radiotherapy (RT) or chemoradiotherapy (CRT) is a potentially curative, non-surgical treatment option for esophageal cancer, although the rate of local failure within the esophagus remains relatively high. Salvage esophagectomy is not regarded as a common treatment for esophageal cancer, since it is a high-risk surgery with a relatively high surgical mortality rate. Salvage endoscopic resection (ER) for local failure is used for treatment when esophageal cancer is localized and superficial. To evaluate to usefulness of salvage ER, the present study reviewed the clinicopathological records and follow-up data of 37 patients that underwent salvage ER for esophageal cancer, following initial treatment with RT or CRT. Salvage ER was conducted on a total of 78 lesions observed in the 37 patients. Since a thick epithelium and lack of normal vessels on the surface of the mucosa are characteristics of esophageal mucosa following RT or CRT, almost all the lesions were detected using iodine dyeing, and not by narrow band imaging. The growth rate of the detected lesions was relatively high, and early treatment was required. No particular complications occurred during the endoscopic treatment. A total of 11 patients survived for >5 years subsequent to initial endoscopic treatment. Only 4 patients succumbed to esophageal cancer. In conclusion, the present study demonstrated that salvage ER following CRT or RT for esophageal cancer is a minimally invasive, safe, adaptive and curative method for superficial lesions without distant metastases in patients with esophageal cancer with local failure following CRT or RT.Keywords
This publication has 26 references indexed in Scilit:
- Counter Traction Makes Endoscopic Submucosal Dissection EasierClinical Endoscopy, 2012
- Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Failure patterns in patients with esophageal cancer treated with definitive chemoradiationCancer, 2011
- Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancerBritish Journal of Cancer, 2010
- Factors Predictive of Tumor Recurrence and Survival After Initial Complete Response of Esophageal Squamous Cell Carcinoma to Definitive ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Indications and outcome of salvage surgery for oesophageal cancer☆European Journal of Cardio-Thoracic Surgery, 2008
- Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trialBritish Journal of Cancer, 2006
- Comprehensive registry of esophageal cancer in Japan, 1999Esophagus, 2005
- Chemoradiotherapy for esophageal cancer: current status and perspectivesInternational Journal of Clinical Oncology, 2004
- Definitive chemoradiation in patients with inoperable oesophageal carcinomaBritish Journal of Cancer, 2004